News – Page 827 – Endpoints News

Two years after a ‘positive’ result tanked their stock, Ovid's Jeremy Levin wins a partner for the PhIII journey

5 years ago

After going ‘crazy’ over the science, Merck signs up a new partner in the hunt for an HIV cure

5 years ago

Another four biotechs scratch out the first number and ask for more as IPO boom continues

5 years ago

AstraZeneca signs computational drug discovery collaboration; J&J-partnered Fate cleared for the clinic

5 years ago

Top biotech analyst projects a gloomy outlook for Pfizer's JAK portfolio

5 years ago

Ophthalmic drugs, cancer cell therapies attract $340M+ on two HKEX biotech debuts

5 years ago

Gilead boasts of positive remdesivir data on mortality — but their analysis provokes the skeptics

5 years ago

Win or lose on the marketing OK, the FDA just gunned down GSK’s bright hopes for their BCMA therapy

5 years ago

Bob Goeltz bolts Unity Biotechnology to become CFO at Arcus Biosciences; John Johnson tapped for his latest CEO gig

5 years ago

Peter Marks on Covid-19 vaccine efficacy, EUAs and challenge trials

5 years ago

Covid-19 roundup: BioNTech going head-to-head with Moderna as PhIII mRNA launch looms; Trial on Shinzo Abe’s ...

5 years ago

A new venture fund amid a pandemic? In the Nordics? Eir Ventures brings it on with €76M first close

5 years ago

Nick Galakatos and the Blackstone team now have a record $4.6B to invest in biopharma, with a big focus on pushing ...

5 years ago

After psilocybin and ketamine, a new biotech comes along developing a drug Scott Gottlieb fought

5 years ago

Biopharma companies pledge $1B to fund antibiotics R&D as field shrivels; Four biotechs hunt $797M+

5 years ago

Forbion spotlights late-stage plays, carves out new €250M growth fund

5 years ago

Merck expands scope of Zymeworks antibody alliance, adding close to $900M in milestones

5 years ago

The home run count: The $100M+ mega-round boom in biotech inspired a $7.3B feeding frenzy — so far this year

5 years ago

NIH kicks off Covid-19 vaccine, monoclonal antibody research network

5 years ago

Stanford star oncology scientist Ed Engleman helped create the immunotherapy field. Now he wants to shake up ...

5 years ago

Out to revive R&D, a resurgent Sanofi pays $150M cash to partner up with a pioneering protein degradation player

5 years ago

Another biotech IPO set-up? Multinational biotech leaps from round to round, scooping up cash at a blistering pace

5 years ago

Covid-19 roundup: CDC debating who should get first available vaccines; EU in Gilead talks after US gobbled first ...

5 years ago

A new study points to $6.5B in public support building the scientific foundation of Gilead's remdesivir. Should that ...

5 years ago

First page Previous page 824 825 826827828 829 830 Next page Last page